Page last updated: 2024-09-04

tipifarnib and Leukemia

tipifarnib has been researched along with Leukemia in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (60.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS1
Ahmed, TA; Hayslip, J; Leggas, M1
Fujiwara, S; Nagai, T; Ohmine, K; Ozawa, K; Sakurai, C; Uesawa, M1
Adamson, PC; Arceci, RJ; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Widemann, BC; Wright, JJ; Zannikos, P1
Abboud, CN; Lancet, JE; Liesveld, JL; Lu, C; McNair, C; Menon, A; Rosell, KE; Rosenblatt, JD1
Flournoy, N; Paul, RK; Rosenberger, WF1
Zhang, GS1
Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K1
Chen, W; Chow, A; Hayes, S; Perez-Ruixo, JJ; Zhang, S1
Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ1

Reviews

2 review(s) available for tipifarnib and Leukemia

ArticleYear
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
    Journal of medicinal chemistry, 2010, Oct-14, Volume: 53, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics

2010
Current status of clinical trials of farnesyltransferase inhibitors.
    Current opinion in oncology, 2001, Volume: 13, Issue:6

    Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction

2001

Trials

2 trial(s) available for tipifarnib and Leukemia

ArticleYear
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2011, Volume: 56, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Farnesyltranstransferase; Female; Half-Life; Humans; Infant; Leukemia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Quinolones

2011
Exposure-toxicity relationships for tipifarnib in cancer patients.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Quinolones; Treatment Outcome

2007

Other Studies

6 other study(ies) available for tipifarnib and Leukemia

ArticleYear
Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.
    Leukemia research, 2014, Volume: 38, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia; Quinolones; ras Proteins; Simvastatin

2014
Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
    Leukemia research, 2010, Volume: 34, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia; Quinolones; Signal Transduction; Sirolimus; Tumor Cells, Cultured

2010
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
    Leukemia, 2003, Volume: 17, Issue:9

    Topics: Alkyl and Aryl Transferases; Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Adhesion; Cell Cycle; Cell Movement; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoiesis; Humans; Leukemia; Mice; Mice, Inbred NOD; Mice, SCID; Poly(ADP-ribose) Polymerases; Quinolones; Time Factors; Tumor Cells, Cultured

2003
Quantile estimation following non-parametric phase I clinical trials with ordinal response.
    Statistics in medicine, 2004, Aug-30, Volume: 23, Issue:16

    Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Leukemia; Maximum Tolerated Dose; Quinolones; Regression Analysis; Statistics, Nonparametric

2004
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
    Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7

    Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine

2005
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
    Biochemical pharmacology, 2005, Jun-01, Volume: 69, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones

2005